Degarelix

Degarelix is a synthetic gonadotropin-releasing hormone (GnRH) receptor antagonist used as androgen-deprivation therapy for hormone-dependent prostate cancer. Unlike GnRH agonists, which initially stimulate the GnRH receptor and can cause a temporary testosterone surge, degarelix directly blocks GnRH receptors in the pituitary gland. This rapidly reduces luteinizing hormone and follicle-stimulating hormone secretion and consequently lowers testosterone production by the testes. Degarelix is administered by subcutaneous injection, where the formulation forms a depot that releases the medicine gradually. Treatment generally begins with a loading dose followed by regular maintenance injections. Because degarelix does not produce an initial testosterone surge, additional anti-androgen therapy for surge protection is generally not required at treatment initiation. Its clinical importance relates to its ability to achieve rapid testosterone suppression and maintain castration-level testosterone concentrations in men with hormone-dependent prostate cancer. Degarelix may be used alone as androgen-deprivation therapy or as part of a broader treatment strategy that can include radiotherapy or other prostate-cancer treatments, depending on disease characteristics and the treatment plan established by the healthcare professional.

Degarelix was developed as a GnRH receptor antagonist designed to suppress the hypothalamic-pituitary-gonadal axis without the initial testosterone flare associated with GnRH agonists. Its clinical development included phase 2 dose-finding studies followed by a pivotal phase 3 randomized study comparing degarelix with leuprolide in men with prostate cancer. In the pivotal study, the approved 240 mg loading dose followed by 80 mg monthly maintenance maintained castration-level testosterone in approximately 97% of patients through one year. The United States Food and Drug Administration granted initial approval for degarelix in 2008 for advanced prostate cancer. The European Commission subsequently granted marketing authorization for Firmagon in 2009, and the European Medicines Agency currently lists degarelix for advanced hormone-dependent prostate cancer and, in the European Union, for certain high-risk localized or locally advanced disease in combination with radiotherapy and as neoadjuvant treatment before radiotherapy. Degarelix Accord, a generic formulation, received EU-wide marketing authorization on 29 September 2023.

Degarelix is used as androgen-deprivation therapy for adult men with advanced hormone-dependent prostate cancer. In the European Union, the authorized indication for Firmagon also includes high-risk localized and locally advanced hormone-dependent prostate cancer when used in combination with radiotherapy, as well as neoadjuvant treatment before radiotherapy in appropriate patients. In clinical practice, degarelix may therefore be used as part of a treatment strategy involving hormonal therapy alone or combined with other prostate-cancer treatments according to disease stage, treatment intent, and individual patient factors. Degarelix has also been investigated in combination with other systemic therapies and in different treatment settings, but such investigational uses should not be interpreted as universally approved indications.

Degarelix is administered by subcutaneous injection, generally into the abdominal region, and should not be administered intravenously; intramuscular administration is also not recommended because it has not been adequately studied. For the commonly used adult regimen, treatment begins with a total loading dose of 240 mg given as two separate 120 mg subcutaneous injections. This is followed 28 days later by an 80 mg subcutaneous maintenance injection, with subsequent maintenance doses generally administered every 28 days. The injection site should be varied periodically and areas exposed to pressure, such as near the waistband or ribs, should be avoided. Treatment duration depends on the clinical indication and overall treatment strategy and may be prolonged when ongoing androgen suppression is required. Serum testosterone and prostate-specific antigen (PSA) are used to assess treatment response, and testosterone should be checked when PSA rises or when clinical response appears inadequate. No dose adjustment is generally required for elderly patients or those with mild to moderate renal or hepatic impairment, although caution is appropriate in severe impairment because clinical data are limited.

Common adverse effects of degarelix are related both to testosterone suppression and to the subcutaneous injection. Injection-site reactions such as pain, redness, swelling, induration, or discomfort are frequent and are generally localized and temporary. Other commonly reported effects include hot flushes, increased sweating, weight gain, fatigue, dizziness, decreased libido, erectile difficulties, and changes in liver enzyme levels. Musculoskeletal symptoms, headache, nausea, and changes in metabolic parameters may also occur. Because androgen deprivation reduces testosterone over time, longer-term treatment can contribute to effects such as reduced bone mineral density, changes in glucose tolerance, and alterations in body composition. The severity and combination of adverse effects vary between individuals, and patients should discuss persistent or troublesome symptoms with their healthcare professional rather than changing or stopping treatment independently.

Important risks include severe hypersensitivity reactions such as anaphylaxis, urticaria, and angioedema, for which degarelix should be discontinued and appropriate medical management provided. Androgen-deprivation therapy may prolong the QT interval, so additional caution is warranted in patients with congenital long-QT syndrome, cardiovascular disease, electrolyte abnormalities, a history of significant QT prolongation, or concurrent use of medicines that can prolong the QT interval. Cardiovascular events such as myocardial infarction and stroke have been reported in association with androgen-deprivation therapy, making assessment and management of cardiovascular risk factors important. Liver enzyme elevations can occur, and liver-function monitoring is appropriate in patients with known or suspected hepatic disease. Long-term testosterone suppression may also contribute to decreased bone density, metabolic changes, and impaired glucose tolerance. Degarelix can inhibit male fertility while testosterone remains suppressed. Treatment interruption or discontinuation should be considered when clinically significant toxicity occurs, particularly severe hypersensitivity or other serious adverse reactions.

Before treatment, clinicians should consider the patient's cardiovascular history, risk factors for QT prolongation, liver and kidney function, metabolic status, and baseline prostate-cancer markers. Patients with severe renal or hepatic impairment require particular caution because these populations have limited clinical data. Long-term androgen deprivation can affect bone density and glucose metabolism, so appropriate assessment of bone health and metabolic risk may be required during prolonged treatment. Degarelix itself is not a substrate of the CYP450 system and has not demonstrated clinically important CYP450 induction or inhibition, making conventional metabolism-based drug interactions unlikely. However, medicines known to prolong the QT interval or increase the risk of torsades de pointes should be reviewed carefully because androgen-deprivation therapy may increase QT-related risk. Electrolyte abnormalities should be corrected when relevant, and periodic ECG or electrolyte monitoring may be appropriate in patients with recognized risk factors. Vaccination decisions should be individualized according to the patient's overall cancer treatment plan and immune status; degarelix is not an immunosuppressive biologic and does not generally require the vaccine precautions associated with immunosuppressive therapies.

Confirm the indication and treatment objective before initiating degarelix and document baseline PSA and testosterone values where appropriate. Review cardiovascular history, QT-prolonging medicines, electrolyte abnormalities, liver and renal function, glucose-related risk factors, and bone-health considerations before and during prolonged androgen-deprivation therapy. Explain that the initial dose consists of two abdominal subcutaneous injections and that local injection-site discomfort can occur. Rotate injection sites and avoid areas exposed to pressure. Because degarelix does not produce the testosterone surge associated with GnRH agonists, additional anti-androgen flare protection is generally unnecessary when initiating therapy. Monitor PSA periodically and measure testosterone if PSA rises or the clinical response appears suboptimal. Pharmacists and treatment teams should verify reconstitution, administration, storage, dose timing, and the correct maintenance interval according to the applicable product information. Coordination with oncology, urology, radiation oncology, and other treating professionals is important when degarelix is combined with radiotherapy or additional systemic prostate-cancer therapies.